Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ...
AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted ...
Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years AstraZeneca’s TAGRISSO®(osimertinib) has been approved in the ...
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer. The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for adults ...
(Alliance News) - AstraZeneca PLC a annoncé jeudi que son médicament anticancéreux Tagrisso avait été approuvé aux Etats-Unis ...
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...
Based on LAURA Phase III trial results which showed Tagrisso Tagrisso reduced the risk of disease progression or death by 84% compared to placebo (hazard ratio 0.16; 95% confidence interval 0.10-0 ...
AstraZeneca PLC et Daiichi Sankyo Co Ltd ont annoncé mardi que leur médicament anticancéreux Enhertu avait reçu un examen ...
Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years WILMINGTON, Del., September 26, 2024--(BUSINESS WIRE)--AstraZeneca ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback